Clinical Trial Update: Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1) [Phase 3]

View source ↗

Summary

Phase 3 trial of clopidogrel (COGENT-1) for gastrointestinal events in acute coronary syndrome and myocardial infarction has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Syndrome
• Myocardial Infarction

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)

Snippet

Sponsor: Cogentus Pharmaceuticals | Conditions: Acute Coronary Syndrome, Myocardial Infarction | Phase 3 | Status: TERMINATED